Fig. 3From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a studya Time to nonadherence. Intent to treat population. b Time to start of TEAEs of skin and subcutaneous tissues disorders . Intent to treat populationBack to article page